Overview

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Status:
RECRUITING
Trial end date:
2026-08-06
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Phase:
PHASE4
Details
Lead Sponsor:
Impax Laboratories, LLC
Collaborator:
Amneal Pharmaceuticals, LLC